Inulin and Protein Fermentation in Hemodialysis Patients
Primary Purpose
Chronic Kidney Disease
Status
Completed
Phase
Phase 1
Locations
Belgium
Study Type
Interventional
Intervention
BENEO synergy1
Sponsored by

About this trial
This is an interventional treatment trial for Chronic Kidney Disease focused on measuring Food supplement, Haemodialysis
Eligibility Criteria
Inclusion Criteria:
- Chronic hemodialysis patients on maintenance dialysis treatment.
- 18 years of age or older
- Written informed consent
Exclusion Criteria:
- Use of pre-/pro-/syn- or antibiotics in preceding 4 weeks.
Sites / Locations
- Universitaire Ziekenhuizen Leuven
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
I
Arm Description
BENEO synergy1
Outcomes
Primary Outcome Measures
Decrease p-cresol serum concentration
Secondary Outcome Measures
Decreased generation rate of p-cresol
Decreased serum concentration of related uremic retention solutes
Change in bowel habits as measured by validated constipation scores
inflammation (c-reactive protein)
Full Information
NCT ID
NCT00695513
First Posted
June 10, 2008
Last Updated
September 14, 2011
Sponsor
Universitaire Ziekenhuizen KU Leuven
1. Study Identification
Unique Protocol Identification Number
NCT00695513
Brief Title
Inulin and Protein Fermentation in Hemodialysis Patients
Official Title
A Phase 1/2 Study on the Effects of BENEO synergy1 on the Generation Rate and Serum Concentration of P-cresol and Related Protein-fermentation Endproducts in Haemodialysis Patients
Study Type
Interventional
2. Study Status
Record Verification Date
September 2011
Overall Recruitment Status
Completed
Study Start Date
March 2006 (undefined)
Primary Completion Date
July 2008 (Actual)
Study Completion Date
July 2008 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Universitaire Ziekenhuizen KU Leuven
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
An important group of protein-bound uremic retention solutes originate from protein fermentation in the colon. P-cresol is a putrefaction metabolite of tyrosine. Indole is generated by fermentation of tryptophan. After absorption, the majority of p-cresol and indole are further metabolised and conjugated to form p-cresylsulphate and indoxyl sulphate. There is clear evidence, both in vitro and in vivo, that accumulation of these conjugated fermentation metabolites in kidney disease is correlated with clinical (cardiovascular) endpoints.
Bacterial protein fermentation can be influenced by altering the colonic microenvironment, influencing the ratio of available carbohydrates to nitrogen, by shortening the colonic transit time or a combination of these. From a theoretical point of view, functional foods, i.e. pro-, pre- and synbiotics, fulfil these criteria.
Prebiotics have been defined as non-digestible food ingredients that beneficially affect the host by selectively stimulating growth, and/or activity, of one or a restricted number of bacteria in the colon. Dietary fibre may suppress the generation of bacterial protein fermentation either by altering the colonic microenvironment or by shortening the colonic transit time. Animal and clinical studies evaluating the effect of dietary fibre supplements on the generation of bacterial fermentation metabolites have provided conflicting results. These discrepancies may be related to specific properties of the dietary fibre investigated. Dietary fibre may impair protein assimilation and the fermentability may vary to a substantial extent.
Inulin and oligofructose have attracted much attention recently as nonabsorbable carbohydrates with prebiotic properties. When inulin and oligofructose were added to a controlled diet, significant increases were noted in colonic bifidobacterial populations, and it has been proposed that these changes promote both colonic and systemic health through modification of the intestinal microflora. Inulin and oligofructose are rapidly and completely fermented by the colonic microflora with the production of acetate and other short-chain fatty acids. In healthy individuals, supplementation with a mixture of inulin and oligofructose was shown to lower p-cresol generation. Although data in healthy volunteers are promising, no data are available in hemodialysis patients.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Chronic Kidney Disease
Keywords
Food supplement, Haemodialysis
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
22 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
I
Arm Type
Experimental
Arm Description
BENEO synergy1
Intervention Type
Dietary Supplement
Intervention Name(s)
BENEO synergy1
Other Intervention Name(s)
BENEO, Synergy1
Intervention Description
50/50 v/v inulin/oligofructose 10 gram BID
Primary Outcome Measure Information:
Title
Decrease p-cresol serum concentration
Time Frame
4 weeks
Secondary Outcome Measure Information:
Title
Decreased generation rate of p-cresol
Time Frame
4 weeks
Title
Decreased serum concentration of related uremic retention solutes
Time Frame
4 weeks
Title
Change in bowel habits as measured by validated constipation scores
Time Frame
4 weeks
Title
inflammation (c-reactive protein)
Time Frame
4 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Chronic hemodialysis patients on maintenance dialysis treatment.
18 years of age or older
Written informed consent
Exclusion Criteria:
Use of pre-/pro-/syn- or antibiotics in preceding 4 weeks.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Pieter Evenepoel, MD, PhD
Organizational Affiliation
Universitaire Ziekenhuizen KU Leuven
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Bjorn Meijers, MD
Organizational Affiliation
Universitaire Ziekenhuizen KU Leuven
Official's Role
Principal Investigator
Facility Information:
Facility Name
Universitaire Ziekenhuizen Leuven
City
Leuven
State/Province
Vlaams-Brabant
ZIP/Postal Code
3000
Country
Belgium
12. IPD Sharing Statement
Citations:
PubMed Identifier
18305466
Citation
Meijers BK, Bammens B, De Moor B, Verbeke K, Vanrenterghem Y, Evenepoel P. Free p-cresol is associated with cardiovascular disease in hemodialysis patients. Kidney Int. 2008 May;73(10):1174-80. doi: 10.1038/ki.2008.31. Epub 2008 Feb 27.
Results Reference
background
PubMed Identifier
16990449
Citation
De Preter V, Vanhoutte T, Huys G, Swings J, De Vuyst L, Rutgeerts P, Verbeke K. Effects of Lactobacillus casei Shirota, Bifidobacterium breve, and oligofructose-enriched inulin on colonic nitrogen-protein metabolism in healthy humans. Am J Physiol Gastrointest Liver Physiol. 2007 Jan;292(1):G358-68. doi: 10.1152/ajpgi.00052.2006. Epub 2006 Sep 21.
Results Reference
background
PubMed Identifier
19692415
Citation
Meijers BK, De Preter V, Verbeke K, Vanrenterghem Y, Evenepoel P. p-Cresyl sulfate serum concentrations in haemodialysis patients are reduced by the prebiotic oligofructose-enriched inulin. Nephrol Dial Transplant. 2010 Jan;25(1):219-24. doi: 10.1093/ndt/gfp414. Epub 2009 Aug 19.
Results Reference
derived
Learn more about this trial
Inulin and Protein Fermentation in Hemodialysis Patients
We'll reach out to this number within 24 hrs